3-Deoxyglucosone

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

3-Deoxyglucosone (3-Deoxy-D-glucosone) 是美拉德反应和多元醇途径的反应中间体 (intermediate)。3-Deoxyglucosone 与蛋白质氨基快速反应形成晚期糖基化终产物 (AGEs)，例如咪唑啉酮，它是 3-DG 的最特异 AGE。3-Deoxyglucosone 可以与低葡萄糖协同作用以增强 GLP-1 分泌，可以作为糖尿病生物学检测的标志物。

3-Deoxyglucosone (3-Deoxy-D-glucosone) is a reactive intermediate of the Maillard reaction and the polyol pathway. 3-Deoxyglucosone rapidly reacts with protein amino groups to form advanced glycation end products (AGEs), such as imidazolone, it is the most specific AGE for 3-DG. 3-Deoxyglucosone synergizes with low glucose to potentiate GLP-1 secretion and is considered as a biomarker for diabetes.

3-Deoxyglucosone (80 ng/ml-1000 ng/ml; 1 hour) markedly increases GLP-1 secretion by 1.23-folds in 300?ng/ml or 1000?ng/ml 3DG-treated group. But at alower concentration (80?ng/ml) has no effects.3-Deoxyglucosone (300 ng/ml; 1 hour) dramatically increases intracellular Ca2+ levels by Fluo-3/AM determination (2.5?μM for 30 mins). But 3DG does not affect intracellular cAMP levels in a cAMP Elisa assay.3-Deoxyglucosone (300 ng/ml; 1 hour) significantly increases the protein expression levels of TAS1R2, TAS1R3, and TRPM5 under both glucose-free and highconditions.Western Blot Analysis Cell Line:STC-1 cells Concentration:300?ng/ml Incubation Time:1 hour Result:Upregulated TAS1R2, TAS1R3, and TRPM5 expression.

3-Deoxyglucosone (intragastric administration; 20 mg/kg; single dose)?impairs glucose tolerance with increased AUC, but the plasma glucagon levels are not significantly different. It developes impaired glucose regulation (IGR) with obviously pancreatic islet cell dysfunction in kunming mice and SD-rats.3-deoxyglucosone?(gastric gavage; 5-50 mg/kg; once daily; 2 weeks) is significantly increased in the upper small intestine (1.4-fold), lower small intestine (1.4-fold), ileum (1.4-fold) and colon (two fold) compared with the basal levels in the corresponding control group. In addition, the protein expressions of TAS1R2, TAS1R3 and TRPM5 in both duodenum and colon are significantly decreased.Animal Model:SD rats Dosage:5, 20 and 50 mg/kg Administration:oral administration; once daily; 2 weeks Result:Was capable of accumulating in?intestinal?tissue?and thereby decreased?secretion?of?GLP-1?and insulin. ?

——

Others

Other Targets

GPX | Glucagon Receptor

——

——

4084-27-9

162.14

C6H10O5

>98% (HPLC)

——

[C@H](CC(C=O)=O)([C@@H](CO)O)O

——

(-20℃)

With Ice Pack

≥ 2 years